Article
Sponsored Content
Author(s):
This case study determines the adoption of Waters ACQUITY UPLC and ACQUITY QDa™ technology in contributing to the success of independent pharmaceutical service provider Chromicent, by providing more information faster and earlier in the method development process.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.